Literature DB >> 18398577

Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists.

Srinivas Iyengar1, LeRoy E Rabbani.   

Abstract

The adenosine diphosphate (ADP) receptor antagonists, specifically the class of thienopyridines, have emerged as potent tools in the clinician's arsenal for the treatment of athero-thrombotic disease over the last two decades. Though these medications have been clearly demonstrated to have significant platelet-inhibiting effects, their potential positive impact on other systemic processes has been less well elucidated. Recent evidence points to a number of potential pleiotropic effects of these agents, most notably in the attenuation of several pro-inflammatory pathways, which may be independent of their anti-platelet-aggregating effect. Additionally, several new ADP receptor antagonists are under investigation; it remains to be seen if these agents possess any additional beneficial pleiotropic properties as well.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398577     DOI: 10.1007/s11239-008-0221-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  71 in total

1.  P-selectin induces the expression of tissue factor on monocytes.

Authors:  A Celi; G Pellegrini; R Lorenzet; A De Blasi; N Ready; B C Furie; B Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

2.  Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery.

Authors:  Laura Molero; Antonio López-Farré; Petra J Mateos-Cáceres; Ruth Fernández-Sánchez; María Luisa Maestro; Jacobo Silva; Enrique Rodríguez; Carlos Macaya
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

3.  Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation.

Authors:  Virgilio Evangelista; Stefano Manarini; Giuseppe Dell'Elba; Nicola Martelli; Emanuela Napoleone; Angelomaria Di Santo; Pierre Savi Roberto Lorenzet
Journal:  Thromb Haemost       Date:  2005-09       Impact factor: 5.249

4.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

5.  Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.

Authors:  L M Biasucci; G Liuzzo; R L Grillo; G Caligiuri; A G Rebuzzi; A Buffon; F Summaria; F Ginnetti; G Fadda; A Maseri
Journal:  Circulation       Date:  1999-02-23       Impact factor: 29.690

Review 6.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

Authors:  Y Liu; Y Shakur; M Yoshitake; J Kambayashi Ji
Journal:  Cardiovasc Drug Rev       Date:  2001

7.  An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.

Authors:  P Nurden; P Savi; E Heilmann; C Bihour; J M Herbert; J P Maffrand; A Nurden
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.

Authors:  Robert F Storey; Heather M Judge; Robert G Wilcox; Stan Heptinstall
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

9.  Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure.

Authors:  Karen E Joynt; Wendy A Gattis; Vic Hasselblad; Sergey Y Fuzaylov; Victor L Serebruany; Paul A Gurbel; Laura H Gaulden; G Michael Felker; David J Whellan; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2004-03-15       Impact factor: 2.778

Review 10.  Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.

Authors:  Steven R Steinhubl; Juan J Badimon; Deepak L Bhatt; Jean-Marc Herbert; Thomas F Lüscher
Journal:  Vasc Med       Date:  2007-05       Impact factor: 3.239

View more
  2 in total

Review 1.  Secondary prevention strategies for coronary heart disease.

Authors:  Shepard D Weiner; LeRoy E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

2.  N-(5-Ethylsulfanyl-1,3,4-thiadiazol-2-yl)-2-(4,5,6,7-tetrahydrothieno[3,2-c]pyri-din-5-yl)acetamide.

Authors:  Shuang Zhi; Shuai Mu; Ying Liu; Deng-Ke Liu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.